🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesShould I be worried about my heart rate going up? — my results so far

Should I be worried about my heart rate going up? — my results so far

MikeFit_NJ Wed, Jul 30, 2025 at 2:42 AM 7 replies 1,295 viewsPage 1 of 2
This thread is more than 10 months old. Information may be outdated. Consider searching for more recent discussions.
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
Jul 30, 2025 at 2:42 AM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

What would genuinely help is knowing how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Numbers rather than impressions, if you have them.

14 17LeilaHI, marcus_mpls, DeniseRN_TPA and 11 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Jul 30, 2025 at 2:54 AM#2
MikeFit_NJ said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 36" ✅ Resolved
  2. Triglycerides: 230 → 115 ✅ Resolved
  3. HDL: 36 → 52 ✅ Resolved
  4. Blood pressure: 140/92 → 118/72 ✅ Resolved
  5. Fasting glucose: 125 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Last edited: Jul 30, 2025 at 4:54 AM
15 18HPLC_Greg, LibrarianMeg, bri_stats and 12 others
Reply Quote Save Share Report
KetoKyle
Member
678
3,456
Jul 2024
Utah
Jul 30, 2025 at 3:06 AM#3
labquiet_amy said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
16 19pat_auckland, Dr.GastroMayo, JakeBK_lifts and 13 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Jul 30, 2025 at 3:18 AM#4
MikeFit_NJ said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Second this. Nothing to add that would improve it.

Last edited: Jul 30, 2025 at 9:18 AM
17 20tammy_FL, Dr.LipidDallas, alex_tucson and 14 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Jul 30, 2025 at 4:20 AM#5

Adding the clinical framing, because it changes how the question reads.

6 month update on cardiovascular risk: down 54 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Last edited: Jul 30, 2025 at 8:20 AM
18 21ChrisMacros, KetoKyle, CanadaChris and 15 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register